High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker

International Journal of Cancer

Volumn 99, Issue 3, 2002, Pages 418-423

  Hiraoka, Kei ^a   Hida, Yasuhiro ^a   Miyamoto, Masaki ^a   Oshikiri, Taro ^a   Suzuoki, Masato ^a   Nakakubo, Yoshihiro ^a   Shinohara, Toshiya ^b   Itoh, Tomoo ^c   Shichinohe, Toshiaki ^d   Kondo, Satoshi ^a   Kasahara, Noriyuki ^d   Katoh, Hiroyuki ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TEINE KEIJINKAI HOSPITAL   (Japan)

^c HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Immunohistochemical analysis; Pancreatic carcinoma; Prognostic factor; RCAS1; Tumor associated antigen

Indexed keywords

RCAS1 ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CARCINOMA, PANCREATIC DUCTAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TIME FACTORS;

EID: 0037140959     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10381     Document Type: Article

References (43)

1. The National Cancer Data Base report on pancreatic cancer
2. Japan Pancreatic Cancer Registry: Current status
3. Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-95, using the National Cancer Database
4. Pancreatic cancer surgical practice guidelines
5. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin
6. Survival advantage of combined chemoradiotherapy compared to resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial
7. Pancreaticoduodenectomy for pancreatic adeno-carcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience
8. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors
9. Ki-ras oncogene activation in preinvasive pancreatic cancer
10. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas
11. K-ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma
12. Homozygous deletion map at 18q21.1 in pancreatic cancer
13. DPC4 gene in various tumor types
14. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
15. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: A new marker of DPC4 inactivation
16. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma
17. A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas
18. The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix
19. Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1
20. Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma
21. Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias
22. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1
23. Costimulation, tolerance and ignorance of cytolytic T lymphocytes in immune responses to tumor antigens
24. Decreased expression of CD80 is a marker for increased tumorigenicity in a new murine model of oral squamous-cell carcinoma
25. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy
26. Histocompatibility antigens on murine tumors
27. Identification of human cancers deficient in antigen processing
28. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - A mechanism of immune evasion?
29. Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape
30. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis
31. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor β1
32. The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic and malignant uterine endometrium
33. Tumor-suppressive pathways in pancreatic carcinoma
34. Pancreatic duct hyperplasia to carcinoma
35. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas
36. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM
37. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells vs. autologous mesothelial cells in vitro
38. Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo
39. Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human alpha-fetoprotein gene promoter
40. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression
41. The dominant negative H-ras mutant, N116Y, suppresses growth of metastatic human pancreatic cancer cells in the liver of nude mice